The Prevalence of HIV Drug Resistance and Transmission Risk in Opioid Agonist Treatment

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00857350

Enrollment

Registered

2009-03-06

Start date

2008-06-30

Completion date

2012-09-30

Last updated

2013-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections, HIV Positive, Opioid Agonist Treatment, Opioid Dependence

Keywords

HIV, resistance, opioid dependence

Brief summary

HIV drug resistance presents a significant public heath problem. This proposal is designed to explore the association between ongoing illicit drug use and the prevalence of HIV drug resistance among HIV+ opioid dependent patients receiving opioid agonist treatment with the following hypotheses: 1. Hypothesis 1: The prevalence of HIV drug resistance will range between 10% and 30%. 2. Hypothesis 2: Patients with evidence of ongoing illicit drug use will be more likely to have HIV drug resistance.

Interventions

None listed

Study design

Observational model

ECOLOGIC_OR_COMMUNITY

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Inclusion criteria

* HIV+ * Opioid dependent * Receiving methadone or buprenorphine for at least one month

Exclusion criteria

* age \< 18 years * current dementia; * inability to read or understand English * inability to provide written informed consent

Design outcomes

Primary

Measure	Time frame
HIV drug resistance	Cross sectional

Secondary

Measure	Time frame
Illicit drug use	6 months
HIV transmission risk behaviors	1 year

Countries

United States

Outcome results